Multikinase Inhibition with Tinengotinib in Advanced Solid Tumors: Results from a Multicenter Phase Ib/II Trial
Sarina A. Piha‐Paul, Chih‐Yi Liao, Farshid Dayyani, Nashat Gabrail et autres
0 citationsClinical Cancer Research
Chih‐Yi Liao
Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.
137Publications signalées
1248Citations signalées
3Affiliations récentes
Institutions déclarées
Domaines associés
Cholangiocarcinoma and Gallbladder Cancer StudiesNeuroendocrine Tumor Research AdvancesGastric Cancer Management and OutcomesLung Cancer Research StudiesNeuroblastoma Research and Treatments
Publications récentes
Anti–PD-1 immunotherapy with chemotherapy for poorly chemo-responsive thyroid and salivary gland tumors: The iPRIME study.
Faith Abodunrin, Theodore Karrison, Ari J. Rosenberg, Jeffery Chin et autres
0 citationsJournal of Clinical Oncology
[212Pb]VMT-alpha-NET for advanced SSTR+ NETs: safety and preliminary efficacy results from cohorts 1 and 2 of the dose escalation phase
MD, Thorvardur Halfdanarson,, Richard L. Wahl, Lilja B. Sólnes, Savitha Balaraman et autres
0 citationsEndocrine Abstracts
Evaluating the role of postoperative long-acting somatostatin analogue therapy in patients with metastatic neuroendocrine tumors undergoing surgical debulking
MD Theodoros Michelakos, MD Joseph Tobias, Sara Abou Azar, Blasé N. Polite et autres
0 citationsEndocrine Abstracts
Real World Outcomes with Chemotherapy and Immunotherapy in Metastatic Poorly Differentiated Gastroenteropancreatic Neuroendocrine Carcinomas
Rushabh Gujarathi, Samantha Kwock, Faith Abodunrin, Namrata Setia et autres
0 citationsEndocrine Abstracts
Phase Ib multicenter study of anti-TIM-3 (S095018/Sym023) in combination with anti-PD-1 (Sym021) in patients with advanced/metastatic recurrent biliary tract cancer
François Ghiringhelli, R. Kim, T. Macarulla, I. Moreno et autres
2 citationsJournal for ImmunoTherapy of Cancer
634 γ-H2AX Immunohistochemistry as a Screening Tool for BRCA-Mutated Carcinomas and a Potential Indicator of PARP Inhibitor Resistance
Mina Farag, L Alpert, Andrea D. Olivas, Shu-Yuan Xiao et autres
0 citationsLaboratory Investigation
635 Rethinking Stability: Are MSH6-MSS Tumors Truly MSS? Two Biologic Subtypes with Divergent Therapy Response
Mina Farag, Peng Wang, Manik Amin, Chih‐Yi Liao et autres
0 citationsLaboratory Investigation
Phase I study of fulvestrant in combination with 177 Lu-DOTATATE for advanced pancreatic neuroendocrine tumors.
Sarah Martin, Aurelie Desgardin, Nicholas Feinberg, Theodore Karrison et autres
0 citationsJournal of Clinical Oncology
Safety and preliminary efficacy results of [ 212 Pb]VMT-a-NET in advanced somatostatin receptor subtype 2 (SSTR2)-expressing neuroendocrine tumors (NETs).
Þorvarður R. Hálfdánarson, Richard L. Wahl, Lilja B. Sólnes, Savitha Balaraman et autres
1 citationJournal of Clinical Oncology
Tinengotinib for adults with advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 trial
Milind Javle, Christos Fountzilas, Chih‐Yi Liao, Meredith S. Pelster et autres
8 citationsThe Lancet. Gastroenterology & hepatology
Data from Final Results from a First-in-Human Phase I Study of the Dual Isocitrate Dehydrogenase (IDH) 1/2 Inhibitor, LY3410738, in Advanced Solid Tumors Harboring IDH1 or IDH2 Mutations
James J. Harding, Do‐Youn Oh, Teresa Macarulla, Lipika Goyal et autres
0 citations
BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref et Europe PMC, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune réponse conservée. Sources et limites.